Eupraxia Pharmaceuticals Inc.
NCM: EPRXLive Quote
About Eupraxia Pharmaceuticals Inc.
Healthcare
Biotechnology
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
📊 Fundamental Analysis
Eupraxia Pharmaceuticals Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -68.8%, which indicates that capital utilization is currently under pressure.
At a current price of $6.86, EPRX currently sits at the 61st percentile of its 52-week range (Range: $2.96 - $9.32).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$548.09M
Trailing P/E
--
Forward P/E
-10.68
Beta (5Y)
1.42
52W High
$9.32
52W Low
$2.96
Avg Volume
220K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App